Drug Profile
STP 602
Alternative Names: STP-602Latest Information Update: 22 Sep 2016
At a glance
- Originator Sirnaomics
- Class Antivirals; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Zika virus infection
Most Recent Events
- 14 Sep 2016 Discontinued - Preclinical for Zika virus infection in USA (Parenteral)
- 08 Sep 2016 Preclinical trials in Zika virus infection in USA (Parenteral)
Development Overview
Introduction
Sirnaomics was developing small interfering RNA (siRNA) candidate STP 602 for Zika virus infection. The drug was in preclinical stage of development. However, development of the candidate was discontinued as it does not appear in the company pipeline anymore.
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class Antivirals, Small interfering RNA
- Mechanism of Action RNA interference
-
WHO ATC code
J05 (Antivirals for Systemic Use)
-
EPhMRA code
J5 (Antivirals for Systemic Use)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Zika virus infection | - | - | Discontinued (Preclinical) | USA | Parenteral / unspecified | Sirnaomics | 14 Sep 2016 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Sirnaomics | Originator | USA |
| Sirnaomics | Owner | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 14 Sep 2016 | Phase Change - Discontinued(Preclinical) | Discontinued - Preclinical for Zika virus infection in USA (Parenteral) Updated 22 Sep 2016 |
| 08 Sep 2016 | Phase Change - Preclinical | Preclinical trials in Zika virus infection in USA (Parenteral) Updated 22 Sep 2016 |
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG